|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
InScape(R) ER, Quant. IHC w/Interpretation [70183X]
Test Code70183
CPT Codes
*ERRO (x0)
Preferred Specimen
1 Block Formalin Fixed Paraffin Block
Instructions: Please include surgical pathology report.
Per ASCO/CAP guidelines, ER (Estrogen Receptor) and PR
(Progesterone Receptor) positivity requires at least 1%
of tumor cells to show positive nuclear staining of any
intensity.
A negative result for ER and PR will be reported if < 1%
of tumor cells show staining.
Instructions: Please include surgical pathology report.
Per ASCO/CAP guidelines, ER (Estrogen Receptor) and PR
(Progesterone Receptor) positivity requires at least 1%
of tumor cells to show positive nuclear staining of any
intensity.
A negative result for ER and PR will be reported if < 1%
of tumor cells show staining.
Minimum Volume
1 Block
Other Acceptable Specimens
3 Slides Unstained, positively charged slides
IHC Specimen Transport Kit; Room Temperature;
Stability:
__Room Temperature: Indefinitely
__Refrigerated: Indefinitley
__Frozen: Do Not Freeze
IHC Specimen Transport Kit; Room Temperature;
Stability:
__Room Temperature: Indefinitely
__Refrigerated: Indefinitley
__Frozen: Do Not Freeze
Transport Container
IHC Specimen Transport Kit
Transport Temperature
Room Temperature
Specimen Stability
Room Temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Do Not Freeze
Refrigerated: Indefinitely
Frozen: Do Not Freeze
Methodology
Immunohistochemistry (IHC)
Setup Schedule
Monday-Friday Morning
Report available: Next Day
Report available: Next Day
Reference Range
See Medical Report
Clinical Significance
Breast cancer is a heterogeneous disease and there is a continual drive to identify markers that will aid in predicting prognosis and response to therapy. Estrogen receptor (ER) is probably the most powerful predictive marker in breast cancer management, both in determining prognosis and in predicting response to hormone therapies.
